M/S UCB FARCHIM SA v. M/S Cipla Ltd.

In the high-stakes world of pharmaceutical patents, the instinct to rush to the highest court for relief is understandable—but it can also be fatal to your case. The dispute between UCB Farchim SA and Cipla Ltd. is a textbook example of how choosing the wrong legal door can slam your chances of ever being heard. This case underscores a critical lesson for founders and IP professionals: when the law provides a specific appellate pathway, bypassing it in favor of a writ petition can result in immediate dismissal.

UCB Farchim SA, a Swiss pharmaceutical company, found itself at odds with orders passed by the Assistant Controller of Patents that rejected its patent applications or related documents. Rather than following the statutory route designed for challenging such decisions, UCB Farchim chose to approach the High Court directly through writ petitions. The respondent in the matter was Cipla Ltd. and others, an Indian pharmaceutical major with its own interests in the patent landscape. The dispute arose against the backdrop of the 2005 Amendment Act to the Patents Act, which introduced significant changes to the framework governing pre-grant and post-grant opposition procedures—reshaping how patent applications could be contested before and after grant.

UCB Farchim's central argument rested on its right to seek judicial review of the Assistant Controller's orders through a writ petition under Article 226 of the Constitution. The company appeared to contend that the rejections warranted immediate intervention by the High Court. On the other side, the respondents and the court itself examined the statutory scheme of the Patents Act with particular attention to the pre-grant and post-grant opposition mechanisms introduced by the 2005 Amendment Act. The legal friction centered on a fundamental question: when a specialized statutory remedy exists, can a party bypass it and invoke the extraordinary jurisdiction of the High Court? The court scrutinized whether the writ route was even available given the comprehensive framework the Patents Act had put in place.

The court dismissed the petitions, holding that a writ petition under Article 226 was not the appropriate remedy to challenge orders passed by the Assistant Controller of Patents. Instead, the court made clear that any party aggrieved by such orders should file an appeal before the Intellectual Property Appellate Board (IPAB) under Section 117A of the Patents Act. By directing litigants to the statutorily prescribed appellate forum, the court reinforced the principle that statutory remedies must be exhausted before extraordinary constitutional jurisdiction can be invoked. The petitions were disposed of without reaching the merits of the underlying patent disputes.

For founders, startup leaders, and IP professionals, the lesson is unambiguous: know your appellate pathway before you litigate. The Patents Act provides a structured, specialized route for challenging decisions of the patent office—through appeals to the IPAB under Section 117A. Treating the High Court's writ jurisdiction as a shortcut not only wastes time and resources but can result in outright dismissal without your arguments ever being heard on the merits. Always map out the statutory remedies available under the relevant IP law before deciding on a litigation strategy. In IP disputes, the right forum is just as important as the right argument.